Studies for people with memory loss
Alzheimer's Disease Ketogenic Diet Retention and Feasibility Trial (KDRAFT) The purpose of this study is to evaluate if patients with Alzheimer’s disease can stay on a very low carbohydrate (ketogenic) diet and if this diet is beneficial in Alzheimer’s disease. The study duration is 4 months where participants will consume a ketogenic diet for 3 months. Study procedures include blood draws, cognitive testing, DEXA scans, MRI’s and questionnaires. Participants will be compensated a total of $125 upon study completion. All participants are required to have a study partner for participation in this research study. Funding for this study is provided by a grant from Frontiers Pilot and Collaborative Studies Funding Program and the University of Kansas Alzheimer’s Disease Center Pilot Program.
Supporting Family Caregivers with Technology for Dementia Home Care (FamTechCare) This study will test whether in-home monitoring and expert feedback on behavior problems will reduce stress, reduce behavior frequency and improve caregiver confidence over 3 months. We will provide you an iPad mini, visit your home to set up the iPad mini and train you to use software to record the situations. You choose which situations to videotape and submit to the experts for their review. We will come back to your home at 1 month and 3 months of participation. Internet connection is required for study participation.
Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine (STEADFAST) This study is enrolling participants who have mild Alzheimer's Disease (AD) in a trial to determine if cognitive functioning can be improved after treatment with azeliragon. Study procedures include MRI's, pen and paper thinking tests, interviews/questionnaires, blood draws for lab tests, physical and neurological exams, ECG's. Those who qualify will be randomized to receive study drug or placebo for 18 months. Participants will attend 9 study visits over the course of 23 months and will be compensated $50 for each study visit. For each visit with an MRI, you will receive an additional $25.
Trial of Oxaloacetate in Alzheimer’s Disease (TOAD) Oxaloacetate (OAA) is a natural chemical that has been shown to have an effect on the brain’s ability to use energy. Researchers believe that the parts of some brain cells that produce energy may be linked to symptoms of Alzheimer’s disease (AD). The TOAD study is designed to determine the safety and tolerability of OAA at doses up to 2 grams per day in people with AD. To qualify, you must be age 50-85 with a diagnosis of AD and be generally healthy. The study involves 3 visits to the clinic over a 6 week period. Procedures will include blood draws, PET and MRS scans (similar to MRI), pen and paper thinking tests, vital signs, and questions about your health. Participants will receive a total of $150 for completing the study.
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease (ENGAGE) The purpose of this study is to evaluate the safety and efficacy of an investigational medicine in individuals with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease (AD). Participants who qualify will receive either a low dose or high dose of the study medication or a placebo (33% chance of receiving placebo) via monthly in-clinic IV infusions for a period of 18 months. Study procedures include MRI's, PET scans, ECG's, pen and paper thinking tests, interviews/questionnaires, blood draws for lab tests, and physical and neurological exams. Participants will attend approximately 30 visits over a 23 month period and will be compensated $50 for each study visit and an additional $25 for each MRI and each PET scan (total of $1575 for completing all visits and procedures).
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing The Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease (Neurotrope) This study evaluates the safety, tolerability, and efficacy of the study drug, bryostatin, in individuals with moderate to severe Alzheimer's disease. Participation is expected to last about 8 months with up to 20 visits to the clinic. Study procedures include study drug infusion, CT or MRI brain imaging, ECG's, blood draws for lab tests, physical and neurological exams, memory and thinking tests, and questionnaires/interviews. The participant will receive 14 infusions over the course of 24 weeks (given about every other week) and each infusion will last about 45 minutes. There is a chance of receiving placebo in the study (the chance of placebo varies in the first and second parts of the study). The participant and the study partner will each receive $50.00 for each study visit the participant completes up to (20 visits). If the participant completes all study visits, the participant and study partner may each receive up to $1000.00.
Alzheimer's Prevention Program (APP) This new study is a comprehensive research effort to examine strategies to improve health and reduce your risk for chronic diseases, including Alzheimer's disease. We are now enrolling participants 65 years and older without Alzheimer's or dementia for the Alzheimer's Prevention Program (APP). One of the goals of the APP is to learn about potential risk factors and what protective behaviors can effectively reduce the risk of developing Alzheimer's disease. The program focuses on how exercise and nutrition influence healthy and unhealthy aging. Study subjects will receive a risk assessment with an amyloid PET scan, general health screen, healthy lifestyle prescription, and surveillance examinations at follow ups.
Effect of Aerobic Exercise on Alzheimer's Pathophysiology in Preclinical AD (APEX) This study will examine the effects of aerobic exercise in individuals at high risk for Alzheimer’s Disease, as determined by an amyloid brain imaging scan. Participants must be age 65 or older, have normal cognition, be physically underactive/sedentary, and be identified at screening with brain imaging tests to have the protein called amyloid. Those who qualify will be randomized to either an aerobic exercise group or a control group. This study will observe whether 52 weeks of aerobic exercise will be associated with lower amyloid levels in the brain, as measured by imaging tests.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A-4) This is a study for older individuals who may be at risk for developing memory loss due to Alzheimer’s disease (AD), but who do not currently have symptoms of AD. The A4 study is examining an investigational medicine, Solanezumab, which may reduce the impact of a protein known as “amyloid” forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of Alzheimer’s disease (AD) -related memory loss. This investigational medicine targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD. Participants in this study must be ages 65-85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain, as determined by a PET brain imaging test. Study procedures include PET brain imaging, MRI brain imaging, ECG’s, blood draws for lab work, physical and neurological exams, memory and thinking tests, and questionnaires/interviews. A lumbar puncture procedure is optional. Compensation for each study visit completed will be provided.
None Currently Enrolling.